01.03.22

Practical Advice on Novel Fecal Microbiota Transplantation in CDI

Practical considerations for the future use of novel FMT therapy for patients with recurrent Clostridioides difficile infection.

12.27.21

Results of the PUNCH CD3 Trial: RBX2660 in Recurrent CDI

Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.

10.25.21

Paul Feuerstadt, MD: RBX2660 and FMT for C. difficile Infections

09.09.21

Ferring and subsidiary Rebiotix are developing a microbiota-based live biotherapeutic, RBX2660, against recurrent C. diff.

07.09.21

Ferring’s Microbiota Therapy for C. diff. Shows Promise

02.24.21

Ferring & Rebiotix Joins MyBiotics in Biotherapeutics Deal to Address Vaginal Health

11.04.19

FDA hears testimony on enforcement discretion of FMT for C. diff.

10.14.19

Rebiotix Works With Regulators To Define A New Clinical Pathway

07.03.19

Ken Blount, CSO of Rebiotix Appointed Chairman of MTIG

05.22.19

Microbiome Companies Unite to Push for EU Regulation Reform

01.29.19

C. diff. Foundation Recognizes Rebiotix CEO with 2019 ‘Above and Beyond’ Award

01.22.19

Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments

10.18.18

Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Tool for Clinical Development

04.05.18

Roseville-based Rebiotix sold to Swiss drugmaker Ferring Pharmaceuticals

02.23.18

Rebiotix develops metric for microbiome research

02.17.18

Minnesota researchers help unlock ‘gut science’ cures; The Twin Cities area is emerging as a major player in what could become a multibillion dollar industry.

02.12.18

How’s your gut bacteria? Minnesota-based Rebiotix unveils new system to measure microbiome changes

11.14.17

“C. difficile Infection Awareness Month” Brings Light to Hospital Infections

08.23.17

Roseville-based Rebiotix in Race to Develop Therapy for Deadly Intestinal Infection

08.13.17

Drugmakers tackle ‘ick’ factor with fecal transplant therapies

08.11.17

Interview – Rebiotix tries to get one up over Seres

08.08.17

Rebiotix launches late-stage superbug trial for microbiome-based drug

04.13.17

Microbiome specialist Rebiotix chalks up C. diff trial success

04.13.17

Rebiotix Microbiome Drug Success Against C. diff. Infection

04.13.17

Rebiotix Gut Bug Knocks Out C. diff. in PUNCH Study

03.03.17

Harnessing the Human Microbiome to Treat GI Diseases

09.20.16

Trial to Investigate Fecal Transplant for Pediatric IBD

09.01.16

How Rebiotix Avoids The Typical Biopharma Startup Missteps

12.17.15

Randomized Trial of FMT for Pediatric Ulcerative Colitis Initiated

11.20.15

Enrollment Completed in Microbiota Restoration Trial for Recurrent C. difficile

11.19.15

A Medtech Veteran Takes on C. diff. From the Gut

11.18.15

Rebiotix Wins MN Tekne Award in Healthcare – Small and Growing Category

10.29.15

Life Science Nexus Interviews Lee Jones, CEO

Fall 2015

Rebiotix Profile in LSF MAGAZINE (pages 52-53)

10.21.15

Rebiotix Wins Breakthrough Therapy Designation for RBX2660

10.21.15

Long-term Effects of Fecal Transplants Questioned

10.19.15

New Product in Development Looks to Help Patients with Clostridium difficile (video interview with Lee Jones, the President and CEO of Rebiotix and Erik Dubberke, MD, from the University of Washington School of Medicine during the annual ID Week conference in San Diego)

10.15.15

FDA designates recurrent C. difficile treatment as breakthrough therapy

10.13.15

Rebiotix says lead product to treat gastrointestinal infection scores Breakthrough Therapy designation from US FDA

05.29.15

Women in Business 2015: Lee Jones, Rebiotix

02.03.15

Women in Business Q&A: Lee Jones, Founder, President, Rebiotix

12.01.14

The Excrement Experiment Treating disease with fecal transplants

11.20.14

Rebiotix to Use Genetic Analysis’ Microarray Tools in Biotherapeutics Development Efforts

11.18.14

Genetic Analysis pens first pharma collaboration with US Rebiotix

10.01.14

Our Body’s Secret Weapon—The Human Microbiome

09.24.14

Episode 14-38 BioTech Nation: Dealing with Bacterial Infections and Pandemics

09.18.14

Rebiotix Banks on Minnesota Angel Tax Credit

09.12.14

How to Become a Successful Entrepreneur in Minnesota

08.18.14

Should We Regulate Poop as a Drug?

08.11.14

Rebiotix CEO Banks on Investor Cash and Promising Biologic Solution

07.23.14

The Infection-Busting Treatment Payers Don’t Want to Talk About

07.07.14

Superbug weapon has ‘yuck factor’ but big promise

07.02.14

Fecal Transplants: A Blunt Approach

05.08.14

Fecal transplantation poses dilemma for FDA

05.14.14

For her second venture, medical device veteran dives into biotech

04.07.14

Treatment of last resort for C. difficile infection

02.26.14

FDA Provides Clearer Guidance on Use of Fecal Transplants to Treat Troublesome Bacteria

11.03.13

Interview with Lee Jones, CEO of Rebiotix, on GMSP Business (You Tube)

11.13

Leaders in Health Care 2013: Startup

09.27.13

Rebiotix Seeking to Pioneer Microbiota Restoration

09.25.13

LifeScience Alley to feature 10 “cutting-edge” companies

09.13.13

Venture Finance conference preview: Who’s who

07.30.13

Rebiotix Receives FDA Approval For Clinical Trial Of First Bacteria-Based Medicine To Combat C. Diff Infection

06.24.13

Rebiotix Inc. attends Springboard: Life Science 2013 Bootcamp